Vessel-Organ Interaction Research Center, VOICE (MRC), Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu, 41566, Republic of Korea.
National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, USA.
Arch Pharm Res. 2022 Jun;45(6):401-416. doi: 10.1007/s12272-022-01389-z. Epub 2022 Jun 27.
Cancer creates a complex tumor microenvironment (TME) composed of immune cells, stromal cells, blood vessels, and various other cellular and extracellular elements. It is essential for the development of anti-cancer combination therapies to understand and overcome this high heterogeneity and complexity as well as the dynamic interactions between them within the TME. Recent treatment strategies incorporating immune-checkpoint inhibitors and anti-angiogenic agents have brought many changes and advances in clinical cancer treatment. However, there are still challenges for immune suppressive tumors, which are characterized by a lack of T cell infiltration and treatment resistance. In this review, we will investigate the crosstalk between immunity and angiogenesis in the TME. In addition, we will look at strategies designed to enhance anti-cancer immunity, to convert "immune suppressive tumors" into "immune activating tumors," and the mechanisms by which these strategies enhance effector immune cell infiltration.
癌症会形成一个由免疫细胞、基质细胞、血管以及各种其他细胞和细胞外成分组成的复杂肿瘤微环境（TME）。了解并克服 TME 内的这种高度异质性和复杂性，以及它们之间的动态相互作用，对于开发抗癌联合疗法至关重要。最近的治疗策略，包括免疫检查点抑制剂和抗血管生成药物，给临床癌症治疗带来了许多变化和进展。然而，免疫抑制性肿瘤仍然存在挑战，这些肿瘤的特点是缺乏 T 细胞浸润和治疗耐药性。在这篇综述中，我们将研究 TME 中免疫和血管生成之间的串扰。此外，我们还将探讨旨在增强抗癌免疫、将“免疫抑制性肿瘤”转化为“免疫激活肿瘤”的策略，以及这些策略增强效应免疫细胞浸润的机制。
